Pharming (PHAR) Income from Continuing Operations (2020 - 2026)
Pharming (PHAR) posted Income from Continuing Operations of 4452000.0 for Q1 2026, down 143.18% on a QoQ basis from 10310004.8 in Q4 2025, and down 243.61% year-over-year from 3099992.96 in Q1 2025.
Pharming (PHAR) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Pharming's Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 4452000.0 for Q1 2026.
- Quarterly Income from Continuing Operations fell 243.61% year-over-year to 4452000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 11487026.5 (up 149.99% YoY) and the FY2025 annual result came in at 2537000.0, up 121.43% from the prior year.
- Income from Continuing Operations was 4452000.0 for Q1 2026 at Pharming, down from 10310004.8 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 37900000.0 in Q4 2022 and bottomed at 22451000.0 in Q2 2024.
- A 5-year average of 751529.74 and a median of 1514002.5 in 2024 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations tumbled 603.58% — and 2025, when it surged 300.47%.
- Pharming's Income from Continuing Operations stood at 37900000.0 in 2022, then tumbled by 135.56% to 13476000.0 in 2023, then jumped by 61.84% to 5143000.0 in 2024, then jumped by 300.47% to 10310004.8 in 2025, then plunged by 143.18% to 4452000.0 in 2026.
- Business Quant data shows PHAR's Income from Continuing Operations at 4452000.0 in Q1 2026, 10310004.8 in Q4 2025, and 17.9 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Pharming | 8.69 Bn | 8.64 Bn | 65.80 Mn | -4.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.45 Mn |
| Dec 31, 2025 | 10.31 Mn |
| Sep 30, 2025 | 17.90 |
| Jun 30, 2025 | 5.63 Mn |
| Mar 31, 2025 | 3.10 Mn |
| Dec 31, 2024 | -5.14 Mn |
| Sep 30, 2024 | 1.51 Mn |
| Jun 30, 2024 | -22.45 Mn |
| Mar 31, 2024 | -4.18 Mn |
| Dec 31, 2023 | -13.48 Mn |
| Sep 30, 2023 | 3.15 Mn |
| Jun 30, 2023 | -15.69 Mn |
| Mar 31, 2023 | -18.13 Mn |
| Dec 31, 2022 | 37.90 Mn |
| Sep 30, 2022 | 9.50 Mn |
| Jun 30, 2022 | 21.59 Mn |
| Mar 31, 2022 | 3.60 Mn |
| Dec 31, 2021 | 15.19 Mn |
| Sep 30, 2021 | -17.81 Mn |
| Jun 30, 2021 | 12.22 Mn |